Coming soon. The new 50-acre site will offer API process development and manufacturing for oligonucleotides, peptides &conjugates from preclinical stages to commercial manufacturing.
Phase I of this development includes a large-scale manufacturing plant for oligonucleotides, peptides, and related synthetic conjugates. Operations are expected to commence in 2027.
